Browse studies

Find your next paid study

4,344 recruiting studies matching your filters

A Randomized Controlled Trial Evaluating the Effect of the Oxytocin Infusion Rate on Fetal Heart Rate Changes and Maternal-Fetal Outcomes During the Initiation of Combined Spinal-Epidural Labor Analgesia

The reported risk of nonreassuring fetal heart trace following neuraxial analgesia is 3-23%. This variability may be due to fluid and oxytocin management prior…

Fetal Bradycardia Complicating Labor and DeliveryFetal Bradycardia During LaborFetal Heart Rate or Rhythm Abnormality Affecting Fetus

Estimated

~$25 – $1,500

Actual pay is set by the research site.

Unyime ItukNCT03232918

Observational

A Randomized Trial of Double Voiding Versus Usual Voiding to Reduce the Incidence of Urinary Tract Infections in Kidney Transplant Recipients

Urinary tract infections (UTI) are common in kidney transplant recipients and are an important cause of illness and hospital admissions. Past studies have show…

Urinary Tract InfectionsKidney Transplant; Complications

Estimated

~$10 – $750

Actual pay is set by the research site.

Weill Medical College of Cornell UniversityNCT05711446

Observational

Clinical Study on the Impact of Electronic Cigarette Temperature and Solvent on Biomarkers of Oxidant Exposure

This project seeks to determine how e-cigarette (EC) physical design features, including those that allow the user to manipulate the quality and quantity of ae…

Oxidative StressTobacco UseElectronic Cigarettes

Estimated

~$10 – $750

Actual pay is set by the research site.

Milton S. Hershey Medical CenterNCT07612696

Phase 1

Phase I Study of Vaccination With DC/MM Fusion Cells in Combination With BCMA Directed CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (B…

Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma

Estimated

~$150 – $4,500

Actual pay is set by the research site.

David AviganNCT07377435

Phase 4

A Randomized Controlled Trial to Evaluate the Effectiveness of Gentamicin Bladder Instillation on CAUTI

Urinary tract infections in catheterized patients is an unacceptable complication and has been termed a 'never event' by the Center for Medicare \& Medicaid Se…

Catheter Infection

Estimated

~$25 – $1,000

Actual pay is set by the research site.

St. Joseph's Hospital and Medical Center, PhoenixNCT06332040

Phase 1

GLP-1 Receptor Agonist Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To …

Pancreatic CancerColorectal CancerHepatocellular Carcinoma

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of ArizonaNCT07627191

Phase 2

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection

The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The…

Chronic Pseudomonas Aeruginosa InfectionCystic Fibrosis (CF)

Estimated

~$75 – $2,800

Actual pay is set by the research site.

BiomX LtdNCT06998043

Phase 1

A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced…

Solid TumorBiliary Tract CancerHead and Neck Squamous Cell Carcinoma+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

TiumBio Co., Ltd.NCT05784688

Phase 1

A Phase I Study to Determine the Safety and Tolerability of BI 3820768 in Patients With Advanced Relapsed or Refractory Germ Cell Tumours, Endometrial Cancer, or Ovarian Cancer

This study is open to adults with advanced germ cell tumours, endometrial cancer, or ovarian cancer whose previous treatments were not successful. People can j…

Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Boehringer IngelheimNCT07306559

Observational

Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions. Aim 3: Assess the Feasibility and Acceptability of the PINPOINT Intervention.

Our overarching goal is to adapt and test the PINPOINT intervention -PatIent Navigation for the Prevention of CervIcal CaNcer inTervention. We will test the PI…

DiabetesCervical Cancer (Early Detection)Obesity & Overweight

Estimated

~$10 – $750

Actual pay is set by the research site.

University of FloridaNCT07351110

Phase 1

A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator's Choice of Adjuvant Chemotherapy in Participants With Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.…

Pancreatic Ductal Adenocarcinoma

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Astellas Pharma Global Development, Inc.NCT07024615

Genetic Studies of Chronic Active Epstein-Barr Virus Infection

Epstein-Barr virus (EBV) is a member of the human herpes virus family that infects more than 95 percent of the U.S. population. Most infections occur in childh…

Chronic Active Epstein-Barr Virus

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Allergy and Infectious Diseases (NIAID)NCT00032513